Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 10:12:23743735251331770.
doi: 10.1177/23743735251331770. eCollection 2025.

Glioblastoma Patient and Caregiver Perspectives of Treatment Side-Effects and Information Provision

Affiliations

Glioblastoma Patient and Caregiver Perspectives of Treatment Side-Effects and Information Provision

Sharon Fernandez et al. J Patient Exp. .

Abstract

Chemoradiotherapy treatment for glioblastoma causes acute and long-term toxicities, negatively impacting quality of life. Patients require evidence-based, yet understandable information regarding treatment-induced toxicities to increase preparedness for treatment. A repeat cross-sectional, qualitative design was used. Semi-structured interviews were conducted with glioblastoma patients and their caregivers at set timepoints: prior to (T1), during (T2), and post (T3) chemoradiotherapy. Interviews were recorded, transcribed verbatim, and thematically analyzed. In total, 19 patients and 12 caregivers were interviewed. Three main themes emerged. (1) Navigating information materials, (2) Lack of awareness and understanding of chemoradiotherapy-induced toxicities, (3) The actual experience and impact of chemoradiotherapy toxicities. There is a discrepancy between the treatment information materials provided and patient expectation and experience of toxicities during and after chemoradiotherapy. Current informational resources do not adequately prepare patients or caregivers for the reality of treatment-induced toxicities. Better tailored resources are needed as individual needs fluctuate across the treatment trajectory. Further cross-center investigation is required to understand how we best create a personalized information pathway for glioma patients.

Keywords: Cancer; communication; patient expectations; patient experience; patient perspectives/narratives; qualitative methods; quality improvement; quality of life.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Summary of key interview questions asked at differing timepoints.
Figure 2.
Figure 2.
Recommendations to consider implementing into clinical practice.

Similar articles

References

    1. Lerner A, Palmer K, Campion T, et al. Gliomas in adults: guidance on investigations, diagnosis, treatment and surveillance. Clin Med, (Lond). 2024;24(5):100240. doi:10.1016/j.clinme.2024.100240 - DOI - PMC - PubMed
    1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Suppl 5):v1-v95. doi:10.1093/NEUONC/NOAC202 - DOI - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987‐96. doi:10.1056/NEJMoa043330 - DOI - PubMed
    1. Mohammed S. Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Pract Oncol Radiother. 2022;27(6):1026‐36. doi:10.5603/RPOR.a2022.0113 - DOI - PMC - PubMed
    1. Röttgering JG, Belgers V, Kouwenhoven MCM, et al. Frequency and burden of potentially treatable symptoms in glioma patients with stable disease. Heliyon. 2023;9(2):e13278. doi:10.1016/j.heliyon.2023.e13278 - DOI - PMC - PubMed

LinkOut - more resources